Pharmacokinetics, absolute bioavailability and tolerability of ketamine after intranasal administration to dexmedetomidine sedated dogs by Vlerick, Lise et al.
RESEARCH ARTICLE
Pharmacokinetics, absolute bioavailability and
tolerability of ketamine after intranasal
administration to dexmedetomidine sedated
dogs
Lise VlerickID1*, Mathias DevreeseID2, Kathelijne Peremans3, Robrecht Dockx3,4,
Siska CroubelsID2, Luc Duchateau5, Ingeborgh PolisID1
1 Small Animal Department, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium,
2 Department of Pharmacology, Toxicology and Biochemistry, Faculty of Veterinary Medicine, Ghent
University, Merelbeke, Belgium, 3 Department of Veterinary Medical Imaging and Small Animal
Orthopaedics, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium, 4 Department of
Psychiatry and Medical Psychology, Ghent Experimental Psychiatry (GHEP) lab, Ghent University, Ghent,
Belgium, 5 Biometrics Research Centre, Faculty of Veterinary Medicine, Ghent University, Merelbeke,
Belgium
* lise.vlerick@ugent.be
Abstract
Intranasal ketamine has recently gained interest in human medicine, not only for its seda-
tive, anaesthetic or analgesic properties, but also in the management of treatment resistant
depression, where it has been shown to be an effective, fast acting alternative treatment.
Since several similarities are reported between human psychiatric disorders and canine
anxiety disorders, intranasal ketamine could serve as an alternative treatment for anxiety
disordered dogs. However, to the authors knowledge, intranasal administration of ketamine
and its pharmacokinetics have never been described in dogs. Therefore, this study aimed to
examine the pharmacokinetics, absolute bioavailability and tolerability of intranasal keta-
mine administration compared with intravenous administration. Seven healthy, adult labora-
tory Beagle dogs were included in this randomized crossover study. The dogs received 2
mg/kg body weight ketamine intravenously (IV) or intranasally (IN), with a two-week wash-
out period. Prior to ketamine administration, dogs were sedated intramuscularly with dexme-
detomidine. Venous blood samples were collected at fixed times until 480 min post-adminis-
tration and ketamine plasma concentrations were determined by liquid chromatography-
tandem mass spectrometry. Cardiovascular parameters and sedation scores were recorded
at the same time points. Non-compartmental pharmacokinetic analysis revealed a rapid
(Tmax = 0.25 ± 0.14 h) and complete IN bioavailability (F = 147.65 ± 49.97%). Elimination
half-life was similar between both administration routes (T1/2el IV = 1.47 ± 0.24 h, T1/2el
IN = 1.50 ± 0.97 h). Heart rate and sedation scores were significantly higher at 5 and 10 min
following IV administration compared to IN administration, but not at the later time-points.
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Introduction
Ketamine is a dissociative anesthetic commonly used in veterinary medicine, mainly for
induction and maintenance of anesthesia, but also for pain management in the peri- and
postoperative period [1,2]. Generally ketamine is administered intravenously, intramus-
cularly or subcutaneously. Recently, intranasal administration of ketamine has gained
attention in human medicine. Intranasal drug administration delivers drugs directly to
the central nervous system, bypassing the blood brain barrier and is associated with a fast
onset of action [3,4]. In addition, intranasal drug delivery avoids painful parenteral
administration. Intranasal ketamine has been successfully used for sedation and preme-
dication of pediatric patients [5–7] and in pain management of both children and adults
[8–13]. Another application lies in psychiatry, where intranasal ketamine has been
shown to be safe and effective for the treatment of major depressive disorders [14–16].
Moreover, recently, the US Food and Drug Administration approved S-ketamine nasal
spray as an new therapy for treatment resistant depression. Since anxiety disorders in
dogs show several similarities with human mood disorders [17–23], intranasal ketamine
could also be a valuable alternative treatment for certain canine behavioural disorders.
Brain imaging studies have reported similar abnormalities in regional cerebral blood
flow of certain brain regions in dogs with pathological anxiety and in humans suffering
from depression and anxiety disorders [17–23]. Furthermore, altered perfusion of these
brain regions following intravenous subanesthetic ketamine administration has been
demonstrated both in humans and dogs [24–30]. Additionally, functional imaging stud-
ies have demonstrated altered function of the serotonergic system in several cortical
brain regions, both in humans and dogs suffering from mood and anxiety disorders [31–
33]. Since the management of behavioural disorders in dogs is challenging and treatment
outcome is often unsatisfactory, there is a need for faster and more effective treatment
strategies [34–37]. Therefore, intranasal ketamine could be a promising adjunctive
treatment in the management of canine anxiety disorders, complementary to standard
behavioural therapy and pharmacotherapy. The intranasal route could also offer oppor-
tunities when ketamine is used for its anesthetic, sedative or analgesic properties in small
animals. For example, when intravenous catheter placement is difficult due to medical or
behavioural issues or for the ambulatory treatment of chronic pain. In cats, it has been
demonstrated that intranasal administration of ketamine-midazolam is effective to
induce sedation [38]. Moreover, compared with intramuscular administration of the
same ketamine-midazolam combination, there were no differences in the measured
parameters associated with sedation except for time to sternal recumbency, which was
more rapid in the intranasal group. In rabbits, intranasal ketamine and S-ketamine was
successfully used in combination with medetomidine to induce anesthesia [39]. Induc-
tion was more rapid compared to rabbits receiving medetomidine-ketamine intramuscu-
larly or subcutaneously [40]. As rabbits are easily stressed, rapid onset of induction is
desirable in this species. Intranasal ketamine has also been used in combination with dex-
medetomidine and morphine to provide deep sedation sufficient for routine clinical
examinations in rabbits [41]. However, to the authors knowledge, intranasal ketamine
has never been used in dogs and its pharmacokinetics have never been described. There-
fore, the primary objective of the present study was to determine and compare plasma
concentrations of ketamine after intravenous and intranasal administration of 2 mg/kg
body weight (BW) ketamine in healthy dogs. Secondly, the tolerability of a single intrana-
sal ketamine administration was assessed.
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1. Materials and methods
1.1. Animals
Seven neutered adult laboratory Beagles (5 females, 2 males; age 3.6 ± 1.7 years; weight
12.0 ± 2.6 kg) were included in a randomized crossover study. The animals were classified as
healthy based on general clinical examination. Experiments were approved by the local Ethical
Committee of the Faculty of Veterinary Medicine and of Bioscience Engineering, Ghent Uni-
versity (EC 2018_03) and all manipulations were performed according to good animal prac-
tice. Welfare of the animals was respected at each time and great care was taken to avoid stress
and anxiety. No animals were sacrificed. The dogs were provided by the Small Animal Depart-
ment of the Faculty of Veterinary Medicine and were purchased from Marshall BioResources
(North Rose, New York, United States). The dogs were socially-housed in small groups (2 to 8
dogs), according to the European and Belgian legislation and received environmental enrich-
ment (Directive 2010/63/EU, KB 29/05/2013). The bedding material in the inner part of the
housing facility consisted of wood shavings. The dogs had permanent access to an outside area
of 15 m2 and twice a day, they were allowed to run and play outside in an enclosed play area,
enriched with climbing platforms, hiding places and small bushes. In addition, the dogs were
regularly walked by students of the Faculty of Veterinary Medicine. Food was withheld for at
least 12 hours before the start of the experiments, but water was provided ad libitum.
1.2. Study design
The dogs were randomly allocated to a two-period crossover design by the principal investiga-
tor, using an online randomization program (www.randomizer.org). Two routes of adminis-
tration of ketamine were examined: the intravenous (IV) and the intranasal route (IN).
Following a two-week wash-out period, each dog underwent the same protocol but receiving
ketamine through a different administration route. Prior to each ketamine administration, the
dogs were sedated intramuscular with dexmedetomidine (375 μg/m2 body surface, Dexdomi-
tor1, Orion Corporation, Espoo, Finland). Following the placement of an IV 22G over-the-
needle catheter (Optiva1, Jelco Smiths Medical International Ltd, Rossendale, UK) in one of
the cephalic veins, the dogs were allowed to relax in a quiet room. The first blood sample (T0)
was taken 20 minutes after dexmedetomidine injection and was followed by the administra-
tion of ketamine.
1.3. Drug administration and sample collection
A commercially available racemic ketamine preparation (Nimatek1, Eurovet Animal Health
B.V., Bladel, the Netherlands) was used for IV injection. IV ketamine was administered at a
dose of 2 mg/kg BW through the cephalic catheter, which was flushed with a standardized vol-
ume of saline prior to and following injection. For the nasal spray, an aqueous solution con-
taining 2 mg/kg BW racemic ketamine (Nimatek1, Eurovet Animal Health B.V.) dissolved in
0.9% NaCl was administered to the mucous membranes of the nose using a mucosal atomiza-
tion device (MAD NasalTM, Wolfe Tory Medical, South Salt Lake City, Utah, United States).
The total volume was fixed at 0.5 mL and was divided over the two nostrils. The MAD con-
verted the aqueous solution into a fine mist creating a film coating the nasal mucosa. During
the nasal administration, dogs were held in sternal recumbency with the head and neck gently
dorsoflexed and were kept in this position for approximately 1 min after nasal delivery. Blood
samples (each 2 mL) were collected from the vena jugularis before ketamine administration
(T0) and at 2, 5, 10, 20, 30, 60, 120, 240, 360 and 480 min after IV ketamine administration.
Following IN administration of ketamine, blood samples were taken at 5, 10, 20, 30, 45, 60,
Pharmacokinetics of intranasal ketamine in dogs
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120, 240, 360 and 480 min after dosing. Blood samples were immediately transferred into
tubes containing lithium heparin and separated by centrifugation within 2 h at 3,500 rpm for
10 min. The plasma was harvested and stored at -80˚C until analysis.
1.4. Tolerability assessment
Adverse reactions during and after intranasal drug administration were recorded to assess the
tolerability (sneezing, coughing, head shaking, snorting and licking).
Sedation scores were determined at the same time points of blood collection. The degree of
sedation was assessed with a modified numeric rating scale ranging from 0 (no sedation) to 15
(maximum sedation) [42] (Table 1).
Together with the scoring of sedation, the following physiological variables were moni-
tored: heart rate, obtained by auscultation, respiratory rate, obtained by direct observation of
thoracic excursions and systolic blood pressure, using an ultrasonic Doppler flow detector and
an inflatable cuff.
1.5. Quantification of ketamine in plasma
Sample preparation was done as described by Devreese et al. (2015) [43]. The chromatographic
system consisted of a Waters Alliance 2690 separation module and autosampler of the same
type (Waters, Zellik, Belgium). Chromatographic separation was achieved on an Acquity
UPLC1 BEH C18 column (particle diameter: 1.7 μm) (Waters). The mobile phases were (A)
0.1% formic acid in UPLC water and (B) 0.1% formic acid in methanol. The following gradient
elution program was run: 0–1.0 min (95% A, 5% B), 1.0–2.0 min (linear gradient to 5% A),
2.0–5.5 min (5% A, 95% B), 5.5–6.0 (linear gradient to 95% A), 6.0–10.0 min (95% A, 5% B).
Flow rate was set at 300 μL/min.
Table 1. Numeric sedation rating scale, adapted from Gurney et al. (2009).
Parameter Behaviour of the dog Score
Spontaneous posture Standing 0
Sternally recumbent 1
Laterally recumbent 2
Palpebral reflex Brisk 0
Slow 1
Absent 2
Eye position Forward (normal position) 0
Rotated ventrally 2
Response to sound (handclap) Body movement 0
Head movement 1
Ear twitch 2
No reaction 3
Resistance to lateral recumbency Full (stands) 0
Moderate restraint required 1
Mild restraint required 2
No resistance 3
Overall appearance No sedation apparent 0
Mild sedation 1
Moderate sedation 2
Well sedated 3
https://doi.org/10.1371/journal.pone.0227762.t001
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The LC column effluent was interfaced to a Waters Quattro Premier triple quadrupole
mass spectrometer equipped with a heated electrospray ionization (h-ESI) probe operating in
the positive ionization mode (Micromass Waters, UK). Acquisition was performed in the
selected reaction monitoring (SRM) mode. The two most intense product ions of the precursor
ion were monitored in the SRM mode for quantification and identification, respectively. For
ketamine m/z 238.4> 125.1/179.2 and for the internal standard (d3-ketamine) m/z
241.4> 125.1/179.2. The method was validated according to a protocol previously described
by [43]. The limit of quantification (LOQ) was 20 ng/mL and the linear range was 20–10,000
ng/mL.
1.6. Pharmacokinetic analysis
Plasma concentration-time profiles were modelled by non-compartmental analysis (NCA)
using Phoenix 8.4 (Certara, NJ, USA). Plasma concentrations measured at 360 and 480 min
after ketamine administration fell below the LOQ and were therefore not taken into account
for pharmacokinetic analysis. The following major pharmacokinetic parameters were calcu-
lated: AUC0-4h area under the plasma concentration-time curve from 0 to 4 hours post-admin-
istration; AUC0-1 area under the plasma concentration-time curve from 0 to infinity; Cmax
maximal plasma concentration (IN); C0 plasma concentration at time zero (IV); Tmax time to
maximal plasma concentration (IN); Vd volume of distribution; Cl total body clearance; T1/2el
terminal elimination half-life; kel elimination rate constant. Vd and Cl values after IN adminis-
tration were not corrected for IN bioavailability (F). The absolute IN F, expressed as percent-
age, was calculated according to the following formula:
F ¼ AUC0  inf IN=AUC0  inf IV � 100:
1.7. Statistical analysis
A Student t-test was used to compare both administration routes (IV and IN) for each pharma-
cokinetic parameter. The level of significance was set at 0.05. For the evaluation of heart rate,
respiratory rate, systolic blood pressure and sedation scores, linear mixed models were fitted
onto the data set using dog as a random effect and time, treatment and their interaction as
fixed effects as the data could be assumed to be normally distributed according to the Shapiro-
Wilks test. Next, the two administration routes were compared at seven different time points
(5, 10, 20, 30, 60, 120 and 240 min after ketamine administration) and tested at the Bonferroni
adjusted significance level of 0.05/7 = 0.0071. Measurements at 360 and 480 min were not
included in the analysis since plasma concentrations at these time points were also not taken
into account for pharmacokinetic analysis.
2. Results
Mean ketamine plasma concentration versus time curves for each administration route are dis-
played in Fig 1. Pharmacokinetic results are shown in Table 2. No significant differences in
pharmacokinetic parameters were found between the two administration routes.
Concerning the heart rate, significant differences between the two administration routes
were found at two time points: 5 (p<0.001) and 10 min (p<0.001) after ketamine administra-
tion, with a higher heart rate following IV administration. At the same time points, significant
differences in sedation scores were also observed (p<0.001) with higher sedation scores fol-
lowing IV administration compared to IN administration. No significant differences between
the two administration routes were found for the respiratory rate and systolic blood pressure.
Pharmacokinetics of intranasal ketamine in dogs
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Dogs tolerated the IN administration relatively well. IN administration led to some degree
of nasal irritation, reflected by sneezing, coughing and head shaking in almost all of the dogs
(Table 3). However, these reactions were mild and only occurred immediately after nasal
administration and disappeared fast.
3. Discussion
To our knowledge, this is the first study describing IN administration of ketamine in dogs and
its pharmacokinetics and tolerance. Ketamine was rapidly absorbed after IN administration,
with maximal plasma concentrations at 15 min and as early as 5 min in one subject. IN drug
delivery is known to be associated with rapid drug absorption from the rich, IN vascular bed,
Fig 1. Mean plasma concentrations of ketamine in dogs administered a single dose of 2 mg/kg BW intravenously (IV) or intranasally (IN)
(n = 7, mean ± SD).
https://doi.org/10.1371/journal.pone.0227762.g001
Table 2. Pharmacokinetic parameters of ketamine in dogs administered a single dose of 2 mg/kg BW intravenously (IV) or intranasally (IN) (n = 7, mean ± SD).
Pharmacokinetic parameter IV IN
AUC0-4h (ng.h/mL) 1415.78 ± 338.40 1925.66 ± 789.83
AUC0-1 (ng.h/mL) 1532.31 ± 397.01 2199.27 ± 773.23
Cmax (ng/mL) / 1694.48 ± 876.67
C0 (ng/mL) 9725.69 ± 3121.04 /
Tmax (h) / 0.25 ± 0.14
Vd (mL/kg) 2869.08 ± 570.03 2342.36 ± 2086.60
Cl (mL/h/kg) 1378.09 ± 340.02 1008.68 ± 333.27
T1/2el (h) 1.47 ± 0.24 1.50 ± 0.97
kel (1/h) 0.48 ± 0.07 0.61 ± 0.29
F (%) 100 147.65 ± 49.97
AUC0-4h area under the plasma concentration-time curve from 0 to 4 hours post-administration; AUC0-1 area under the plasma concentration-time curve from 0 to
infinity; Cmax maximal plasma concentration (IN); C0 plasma concentration at time zero (IV); Tmax time to maximal plasma concentration (IN); Vd volume of
distribution; Cl total body clearance; T1/2el terminal elimination half-life; kel elimination rate constant. Vd and Cl values after IN administration were not corrected for
IN bioavailability (F).
https://doi.org/10.1371/journal.pone.0227762.t002
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leading to rapidly attained peak blood levels, as observed in this study [3]. Ketamine was
completely bioavailable following IN administration. This is much higher than the reported IN
bioavailability of 45 and 50% in human studies [44,45]. This can be partially explained by dif-
ferences in anatomy of the nasal cavity between humans and dogs. Following intranasal
administration, ketamine can be delivered directly to the central nervous system, where it can
exert its actions [3,4,46]. This direct nose to brain delivery, bypassing the blood brain barrier,
occurs mainly through the olfactory epithelium, which comprises 77% of the nasal cavity in
dogs [46]. The human olfactory epithelium, on the contrary, is restricted to a small area in the
roof of the nasal cavity and only covers less than 10% of the nasal cavity. The complete IN bio-
availability can further be explained by the fact that the dogs were sedated, which facilitated
nasal drug delivery and is associated with less risk of spilling and swallowing. Moreover, using
a spray device instead of droplet administration of the drug into the nose and dividing the
dose over the two nostrils would also enhance nasal absorption and bioavailability, since this
increases the area over which the drug is spread [7,46].
Total body clearance (Cl) of ketamine was lower compared to other veterinary studies
examining the pharmacokinetics of ketamine in dogs [47–49]. In the study of Pypendop and
Ilkiw (2005), mean Cl after IV administration of ketamine was 3492 ± 1038 mL/h/kg, while
volume of distribution at steady state (Vss) was 4060.3 ± 2405.7 mL/kg. Romagnoli et al.
(2017) reported separate Cl values for S- (4309.2 ± 768 mL/h/kg) and R-ketamine (4048.8 ±
640.8 mL/h/kg) following IV racemic ketamine administration, with a volume of distribution
for the central compartment of 750 ± 370 mL/kg. The study of Sandbaumhu¨ter et al. consisted
of two groups of dogs receiving ketamine, with one group anesthetized with sevoflurane and
one group sedated with medetomidine. In the sevoflurane group, Cl was 3341.4 ± 664.2 mL/h/
kg for R-ketamine and 3490.2 ± 642 mL/h/kg for S-ketamine with Vss of 1630 ± 1170 mL/kg
and 1620 ± 1230 mL/kg respectively. In the medetomidine group Cl was 2844.6 ± 474 mL/h/
kg for R-ketamine and 2745.6 ± 996.6 mL/h/kg for S-ketamine, with Vss of 3370 ± 660 mL/kg
and 3130 ± 660 mL/kg respectively. Elimination half-life was comparable with that reported in
the study of Pypendop and Ilkiw (2005) (1.57 ± 0.61 h), but was longer than documented by
Romagnoli et al. (2017) (0.26 ± 0.12 h for S-ketamine and 0.26 ± 0.09 h for R-ketamine) and
Sandbaumhu¨ter et al. (2016) (0.50 ± 0.04 h for R-ketamine and 0.48 ± 0.42 h for S-ketamine in
the sevoflurane group; 1.14 ± 0.17 h for R-ketamine and 1.11 ± 0.21 h for S-ketamine in the
medetomidine group). The longer half-life of ketamine in the medetomidine group compared
with the sevoflurane group in the study of Sandbaumhu¨tter et al. (2017) indicates a slower
elimination in the latter group. The lower clearance and subsequent longer half-life in the cur-
rent study compared to the literature is in agreement with this and could be explained by the
fact that the dogs were sedated with dexmedetomidine. Dexmedetomidine and medetomidine
are strong inhibitors of the N-demethylation of ketamine to norketamine by competition for
the binding site on cytochrome P450 enzymes [48]. Since the formation of norketamine is a
Table 3. Adverse reactions following intranasal administration of 2 mg/kg BW racemic ketamine in the individual dogs (n = 7).
Dog Sneezing Coughing Head shaking Snorting Licking Duration
Dog 1 - + - - - < 10 sec
Dog 2 + - + + - < 1 min
Dog 3 + + - + + < 1 min
Dog 4 - + - - - < 1 min
Dog 5 + - - + - < 10 sec
Dog 6 + - - + - < 10 sec
Dog 7 - - - - - -
https://doi.org/10.1371/journal.pone.0227762.t003
Pharmacokinetics of intranasal ketamine in dogs
PLOS ONE | https://doi.org/10.1371/journal.pone.0227762 January 13, 2020 7 / 13
major pathway in the biotransformation and hence elimination of ketamine, inhibition of nor-
ketamine formation can explain the slower elimination of ketamine when combined with dex-
medetomidine. Moreover, since ketamine is a drug with a high hepatic extraction ratio in the
dog [50], another explanation for the observed lower clearance and longer half-life could be
the decreased cardiac output and reduced hepatic blood flow associated with dexmedetomi-
dine administration [51,52]. In agreement with this, dexmedetomidine has also been shown to
alter thiopental pharmacokinetics, most probably by decreasing cardiac output and regional
blood flow [53].
Few data are available on ketamine’s effective analgesic serum concentrations. A study of
Bergadano et al. (2009) [54], investigating the analgesic effects of a low-dose constant rate infu-
sion of ketamine, showed that ketamine’s antinociceptive effects were evident when plasma
concentrations ranged between 220–370 ng/mL. Another study investigating antinociceptive
effects of different ketamine infusion regimes found that the serum concentration of ketamine
to produce mechanical antinociceptive effects is above 200 ng/mL [55]. In the present study,
mean Cmax after IN administration was 1694.48 ng/mL and mean plasma concentrations
stayed above 200 ng/mL until 2 h after ketamine administration, indicating antinociceptive
effects in this time frame. This implies that a single IN administration of 2 mg/kg BW keta-
mine has relatively long lasting analgesic effects in dogs. IN ketamine could therefore serve as
a valuable alternative when IV catheter placement is difficult. However, these findings should
be interpreted with caution, since this study was not designed to assess the analgesic or seda-
tive potential of IN ketamine. Further studies evaluating these clinical effects of IN adminis-
tered ketamine at different doses are necessary.
In both groups heart rate was low before ketamine administration, due to the sedation with
dexmedetomidine (47 ± 5 beats per min (bpm) in the IV group and 43 ± 5 bpm in the IN
group). It is known that dexmedetomidine causes bradycardia, with normal expected heart
rates ranging between 45 and 60 bpm [51], which is in agreement with our observations. Fol-
lowing ketamine administration, heart rate increases in both groups, due to ketamine’s sympa-
thomimetic effects [56]. However, the stimulatory effects of ketamine on the cardiovascular
system were attenuated by the dexmedetomidine comedication. Heart rate and sedation scores
were higher following IV administration compared to IN administration the first 10 min after
ketamine administration. Following IV ketamine administration, heart rate increased to
86 ± 22 bpm, while after intranasal administration, only a small increase in heart rate was
observed. These differences in heart rates and sedation scores can be explained by the fact that,
during the first 10 min following ketamine administration, plasma concentrations were higher
following IV administration compared to IN administration.
The seven dogs completed the study without clinical significant or serious adverse events.
The IN administration was easy to perform and generally well tolerated by the sedated dogs,
with short duration mild adverse effects associated with the route of administration. The most
frequently observed adverse event in this study was a short sneezing and snorting reaction,
which was present in 4 out of 7 dogs. A brief episode of sneezing during or after intranasal
administration was also reported in dogs receiving intranasal midazolam [57]. In another
study, examining nasal administration of diazepam in dogs, several dogs developed salivation
and reverse sneezing following intranasal administration [58]. Also in cats, a sneezing and
snorting reaction following intranasal administration of a ketamine-midazolam combination
has been reported [38]. However, in the current study, coughing was also observed in 3 out of
7 dogs and head shaking was present in one dog. These reactions may be due to the bitter taste
of ketamine, which could have caused irritation and an unpleasant sensation in the dogs. In
human medicine, patients receiving intranasal ketamine frequently complain about a bad taste
in the mouth, due to drug runoff into the pharynx [6,9,13,59].
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A limitation of this study is the fact that the dogs were sedated with dexmedetomidine prior
to the ketamine administration. Dexmedetomidine was administered to avoid behavioural and
cardiovascular adverse effects due to the ketamine administration. Dexmedetomidine-keta-
mine is a frequently used combination in veterinary medicine as the two drugs are comple-
mentary to each other and side effects of both drugs are minimized when used together.
Dexmedetomidine may attenuate or prevent tachycardia, hypertension, delirium, excitement
and hallucinations caused by ketamine [51,60]. On the other hand, ketamine may reduce the
bradycardia and hypotension associated with dexmedetomidine administration [61]. How-
ever, the use of co-medication can have an influence on drug disposition and
pharmacokinetics.
Conclusion
IN administration of 2 mg/kg BW ketamine to healthy dogs, sedated with dexmedetomidine,
was well tolerated by all of the dogs. Rapid systemic absorption and complete bioavailability of
IN ketamine were demonstrated. These findings encourage the use of IN ketamine in veteri-
nary medicine, not only as anesthetic, sedative or analgesic but potentially also in the treatment
of dogs with anxiety disorders. Further studies are necessary to assess the clinical effects of IN
ketamine in anxiety-disordered dogs.
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